Financials
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
KLRS Catalyst Timeline
Dated clinical, regulatory and corporate events for Kalaris Therapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Kalaris Therapeutics, Inc.
Upcoming catalysts 2
Event history 37
Past FDA Catalysts and PDUFA Decisions
How KLRS actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2025-12-17 | TH103 | Phase 1a data readout | Phase 1a |
Drug Pipeline Intelligence
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Posoleucel Cell TherapiesCompletedNCT04693637 | Adenovirus Infection | Phase 2/3 | COMPLETED | 26 | Jan 19, 2023 | ||||||
| Posoleucel cells Cell TherapiesCompletedNCT04605484 | BK Virus Nephropathy | Phase 2 | COMPLETED | 61 | Oct 20, 2022 |
Clinical Trial Results
Readouts, endpoints and source filings for every KLRS program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| TH103 | neovascular AMD | Phase 1a | 2025-12-17 | mean 10-letter gain in visual acuityRead More | Kalaris Therapeutics Reports Initial Positive Phase 1a Data for TH103 in Treatment-Na ve Neovascular AMD TH103 showed mean 10-letter gain in visual acuity and rapid, robust anatomic improvement at Month 1, following a siRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| AKKARAJU SRINIVASDirector, 10% Owner | Buy | 244,300 2,224,147 held | $4.83 | 05/20/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in KLRS
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Samsara BioCapital, LLC | 3.5 % (-18.6 %) | 37.23 M | 12.88 M |
Ownership Trends
KLRS Short Interest
Shares sold short, counted twice a month.
Options Data
Option Volume
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
Competitive positioning
How KLRS ranks across every disease it competes in
KLRS News
Kalaris Reports Third Quarter 2026 Financial Results and Provides Business Update
Kalaris Therapeutics reported its Q3 2026 financial results, highlighting a successful technology transfer to a commercial-scale manufacturer. The ongoing Phase 1b/2 study of TH103 in neovascular age-related macular degeneration (nAMD) is experiencing delays, with preliminary data now expected in 2H 2027. The company has $82.9 million in cash, projected to fund operations into 2028.
Read more →Kalaris to Present at Morgan Stanley 24th Annual Global Healthcare Conference
Kalaris Therapeutics announced that its management team will participate in a Fireside Chat at the Morgan Stanley 24th Annual Global Healthcare Conference. The session is scheduled for Tuesday, September 15, 2026, in New York. Chief Executive Officer Andrew Oxtoby and Chief Medical Officer Matthew Feinsod will lead the discussion. Kalaris is currently developing TH103 for neovascular Age-related Macular Degeneration.
Read more →Kalaris Reports Second Quarter 2026 Financial Results and Provides Business Updates
Kalaris Therapeutics reported a net loss of $11.5 million for the second quarter ended June 30, 2026. The company held $93.5 million in cash and marketable securities at the end of the period. This balance is expected to fund operations through the fourth quarter of 2027. Patient dosing is ongoing in the Phase 1b/2 study of TH103 for neovascular AMD.
Read more →Kalaris Expands Leadership Team Appointing Liisa Bayko as Chief Financial Officer
Kalaris Therapeutics appointed Liisa Bayko as chief financial officer. She brings over twenty years of biotechnology finance experience to the role. The hire supports the company as it advances its Phase 1b/2 study of TH103. This trial targets treatment naïve patients with neovascular age-related macular degeneration.
Read more →Kalaris Therapeutics Reports Positive TH103 Phase 1a SAD Results from Expanded Neovascular AMD Cohorts
Kalaris Therapeutics reported positive Phase 1a data for TH103 in neovascular AMD. The drug showed extended intraocular retention with 27- to 53-fold lower Cmax than current anti-VEGF agents. Forty-one percent of treatment-naive patients required no retreatment for four months or longer. Enrollment in the Phase 1b/2 trial continues, with preliminary data expected in the first half of 2027.
Read more →Kalaris Appoints Laurie Keating to Board of Directors
Kalaris Therapeutics appointed Laurie Keating to its board of directors effective August 1, 2026. Morana Jovan-Embiricos stepped down from the board at the same time. Keating brings experience from roles at Alnylam Pharmaceuticals and current board positions at PepGen and Immuneering. The company continues developing TH103 for retinal diseases.
Read more →Kalaris Announces Upcoming Presentation of TH103 Phase 1a Clinical Data at American Society of Retina Specialists; Ph 1b/2 Clinical Trial Actively Enrolling
Kalaris Therapeutics will present Phase 1a data for TH103 at the American Society of Retina Specialists meeting on July 17, 2026. The company also confirmed that its Phase 1b/2 trial for neovascular Age-related Macular Degeneration is actively enrolling and dosing patients. Initial results from this ongoing study are expected in the first half of 2027. These updates support the drug’s development path toward potential Phase 3 trials.
Read more →Kalaris to Present at Clinical Trials at the Summit 2026
Kalaris Therapeutics will present Phase 1a clinical data for TH103 at the Clinical Trials at the Summit 2026. The data focuses on treatment-naïve patients with Neovascular Age-Related Macular Degeneration. The presentation will be led by Dr. Karl Csaky and is scheduled for June 13, 2026, in Las Vegas, NV.
Read more →Kalaris Reports First Quarter 2026 Financial Results and Provides Business Updates Patient screening now underway in the Phase 1b/2 study with the latest drug product batch on track to be
Kalaris Therapeutics, Inc. reported its financial results for the first quarter of 2026 and provided business updates. The company is currently screening patients in its Phase 1b/2 study for the drug TH103, aimed at treating neovascular Age-related Macular Degeneration, with preliminary data expected in the first half of 2027. Kalaris has $104.9 million in cash reserves, projected to fund operations through late 2027, while planned Phase 3 trials are slated for initiation by year-end 2027. However, a continued net loss and rising operational costs were noted in the financial report.
Read more →Kalaris Reports Full Year 2025 Financial Results and Provides Business Updates
Kalaris Therapeutics reported positive initial data from its Phase 1a trial for TH103, aimed at treating neovascular age-related macular degeneration (nAMD), and announced financial results for 2025. The company completed a $50 million private placement and expects its cash reserves will fund operations into the fourth quarter of 2027. While research and development expenses decreased, general administrative expenses rose sharply. Additionally, the net loss for the year was significantly lower than the previous year.
Read more →Forward-Looking Statements & Disclaimer This presentation contains "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange A
Kalaris has provided insights into its forward-looking plans related to its lead drug candidate TH103, intended for retinal diseases. The company has outlined a timeline for clinical trials, however, it warns of various risks and uncertainties inherent to the development process. Additionally, Kalaris indicated it has sufficient cash resources to fund operations into late 2027, following a successful private placement. The drug TH103, which has shown initial promise, aims to address significant unmet medical needs in the market for retinal treatments.
Read more →Kalaris to Present Phase 1 Clinical Data for TH103 at the Macula Society Annual Meeting
Kalaris Therapeutics will present Phase 1 clinical data for TH103 at the Macula Society Annual Meeting from February 25-28, 2026. The therapy, engineered for enhanced VEGF inhibition, targets treatment-naive patients with neovascular age-related macular degeneration. Key details include safety and efficacy outcomes from the study, presented by Dr. Dean Eliott.
Read more →Kalaris Therapeutics Reports Positive Initial Phase 1a Data for TH103 in Treatment-Naïve Neovascular AMD
Kalaris Therapeutics reported positive initial Phase 1a data for TH103 in treatment-naïve patients with neovascular AMD. The data showed significant improvements in visual acuity and retinal anatomy after a single injection. TH103 demonstrated a favorable safety profile, with no serious adverse events reported. The company plans to accelerate its clinical development program based on these results.
Read more →Kalaris Therapeutics Reports Initial Positive Phase 1a Data for TH103 in Treatment-Naïve TH103 showed mean 10-letter gain in visual acuity and rapid, robust
Kalaris Therapeutics reported promising initial data from its Phase 1a study of TH103, indicating significant improvements in visual acuity and retinal anatomy in treatment-naive neovascular AMD patients. The treatment showed a mean gain of 10 letters in visual acuity at Month 1 and was generally well tolerated, prompting plans for further dose escalation. Moreover, a notable pharmacokinetic profile suggested enhanced intraocular retention, which may lead to extended treatment durability. Expected preliminary data from the ongoing Phase 1b/2 study is anticipated in the second half of 2026.
Read more →Kalaris Therapeutics Announces Oversubscribed $50.0 Million Private Placement
Kalaris Therapeutics has announced an oversubscribed private placement that will raise approximately $50 million. The offering, involving both new and existing institutional investors, is set to close soon and will be used to advance the clinical development of TH103 for neovascular AMD, alongside other corporate purposes. The securities will not be registered under the Securities Act, necessitating a registration rights agreement with the investors.
Read more →Kalaris Reports Third Quarter 2025 Financial Results and Provides Business Updates
Kalaris Therapeutics reported its financial results for Q3 2025, highlighting significant corporate milestones and progress in clinical trials. The Phase 1a Single Ascending Dose trial remains on schedule for initial data by year's end, while the Phase 1b/2 trial is currently enrolling participants. The company has substantial cash reserves of $77 million, projected to fund operations into 2027 even as R&D expenses reflect past obligations. Despite a notable net loss, the company is advancing its investigational treatment TH103 aimed at retinal diseases.
Read more →Kalaris Expands Leadership Team Appointing Matthew Gall, MBA, as Chief Financial Officer
Kalaris Therapeutics appointed Matthew Gall as Chief Financial Officer to enhance its leadership team. Gall, with a strong background in biopharma finance, will support the company's growth as it progresses its Phase 1b/2 study for treatment-naïve nAMD patients. His previous experience includes roles at iTeos Therapeutics and Sarepta Therapeutics.
Read more →Kalaris to Present at Stifel 2025 Annual Healthcare Conference
Kalaris Therapeutics will present at the Stifel 2025 Annual Healthcare Conference on November 13, 2025. CEO Andrew Oxtoby and CMO Matthew Feinsod will speak from 3:20 to 3:50 PM ET. The company aims to address major unmet needs in retinal disease treatments. One-on-one meetings will also be available during the event.
Read more →UPDATE – Kalaris Therapeutics Now Enrolling Phase 1b/2 Multiple Ascending Dose Study of TH103 in Neovascular Age-Related Macular Degeneration
Kalaris Therapeutics has begun enrolling patients for a Phase 1b/2 study of TH103, targeting neovascular age-related macular degeneration (nAMD). This study aims to assess safety and efficacy with four monthly doses of TH103. Initial data is anticipated in the second half of 2026, building on findings from an ongoing Phase 1a study.
Read more →Kalaris Reports Second Quarter 2025 Financial Results and Provides Business Updates
Kalaris Therapeutics reported its financial results for Q2 2025, highlighting a net loss of $11.4 million, a significant increase from the previous year. The company continues to enroll patients in a Phase 1 trial for its new anti-VEGF agent, TH103, with initial data expected by Q4 2025. Kalaris currently holds $88.4 million in cash, which is projected to sustain operations through Q4 2026. The upward trend in R&D and administrative expenses indicates growing operational complexities as the company advances its clinical programs.
Read more →